Machine signal
Active cluster sell — 3 distinct insiders, $4.5M, window ends Sep 30, 2026.
Figures computed from official regulatory filings — .
Analysttarget 50.34 USD (+121%) · consensus 4.69/5 · 15 buy · 1 hold · 0 sell
Ownershipinsiders 0.9% · institutions 106.61% · short 15.3% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for NewAmsterdam Pharma Co N.V. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
14 buys101 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Kastelein Johannes Jacob Pieter | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kastelein Johannes Jacob Pieter | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Kastelein Johannes Jacob Pieter | Sell | $1.3M | SEC |
| Davidson Michael H.track record | Buy | $226.5K | conv 71Unusual sizeFirst in 12mo | SEC |
| Smither John W | Sell | $40.5K | SEC |
| Gunning Robert William | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Gunning Robert William | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kooij Louise Frederika | Sell | $92.4K | SEC |
| Kooij Louise Frederika | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kooij Louise Frederika | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kooij Louise Frederika | Exercise | $893.6K | Unusual size | SEC |
| Kooij Louise Frederika | Sell | $990K | SEC |
| Kooij Louise Frederika | Sell | $2.1M | SEC |
| Kooij Louise Frederika | Exercise | $297.5K | SEC |
| Kooij Louise Frederika | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kooij Louise Frederika | Exercise | $178.5K | SEC |
| Kooij Louise Frederika | Sell | $9.2K | SEC |
| Kooij Louise Frederika | Sell | $1.2M | SEC |
| Kooij Louise Frederika | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kooij Louise Frederika | Exercise | $272.5K | SEC |
| Kooij Louise Frederika | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kooij Louise Frederika | Exercise | $600K | SEC |
| Kooij Louise Frederika | Exercise | $54.5K | SEC |
| Kooij Louise Frederika | Sell | $2.3M | SEC |
| Kooij Louise Frederika | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |